Liver‐directed gene therapy for inherited metabolic diseases
Journal of Inherited Metabolic Disease · 2024-01 · 47 (1) · 9-21
DOI: 10.1002/jimd.12709 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 03.01.2024. Verfasst von Julien Baruteau und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Metabolic Medicine, Great Ormond Street Hospital for Children NHS Trust, London, UK. Hauptthemen laut MEDLINE: Liver Diseases, Metabolic Diseases, Hemophilia A. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.
Abstract (Originalsprache)
Gene therapy clinical trials are rapidly expanding for inherited metabolic liver diseases whilst two gene therapy products have now been approved for liver based monogenic disorders. Liver‐directed gene therapy has recently become an option for treatment of haemophilias and is likely to become one of the favoured therapeutic strategies for inherited metabolic liver diseases in the near future. In this review, we present the different gene therapy vectors and strategies for liver‐targeting, including gene editing. We highlight the current development of viral and nonviral gene therapy for a number of inherited metabolic liver diseases including urea cycle defects, organic acidaemias, Crigler–Najjar disease, Wilson disease, glycogen storage disease Type Ia, phenylketonuria and maple syrup urine disease. We describe the main limitations and open questions for further gene therapy development: immunogenicity, inflammatory response, genotoxicity, gene therapy administration in a fibrotic liver. The follow‐up of a constantly growing number of gene therapy treated patients allows better understanding of its benefits and limitations and provides strategies to design safer and more efficacious treatments. Undoubtedly, liver‐targeting gene therapy offers a promising avenue for innovative therapies with an unprecedented potential to address the unmet needs of patients suffering from inherited metabolic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Paediatric Metabolic Medicine, Great Ormond Street Hospital for Children NHS Trust, London, UK.
- University College London Great Ormond Street Institute of Child Health, London, UK.
- National Institute of Health Research Great Ormond Street Biomedical Research Centre, London, UK.
- Telethon Institute of Genetics and Medicine, Pozzuoli, Italy.
- Department of Translational Medicine, Federico II University, Naples, Italy.
- Scuola Superiore Meridionale (SSM, School of Advanced Studies), Genomics and Experimental Medicine Program, University of Naples Federico II, Naples, Italy.
ORCID-Profile: Nicola Brunetti-Pierri
Förderung
- Medical Research Council
Zitieren
APA
Baruteau, J., Brunetti-Pierri, N., & Gissen, P. (2024). Liver‐directed gene therapy for inherited metabolic diseases. Journal of Inherited Metabolic Disease, 47(1), 9-21. https://doi.org/10.1002/jimd.12709
Vancouver
Baruteau J, Brunetti-Pierri N, Gissen P. Liver‐directed gene therapy for inherited metabolic diseases. Journal of Inherited Metabolic Disease. 2024;47(1):9-21. doi:10.1002/jimd.12709
BibTeX
@article{Baruteau2024,
author = {Baruteau, Julien and Brunetti-Pierri, Nicola and Gissen, Paul},
title = {Liver‐directed gene therapy for inherited metabolic diseases},
journal = {Journal of Inherited Metabolic Disease},
year = {2024},
volume = {47},
number = {1},
pages = {9--21},
doi = {10.1002/jimd.12709}
}
EUVIMED